ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $8,767,000 | +408.2% | 235,855 | +601.6% | 0.95% | +170.9% |
| Q2 2020 | $1,725,000 | -36.5% | 33,615 | -61.0% | 0.35% | -33.8% |
| Q1 2020 | $2,715,000 | -33.6% | 86,118 | +25.6% | 0.53% | +25.7% |
| Q4 2019 | $4,089,000 | +964.8% | 68,570 | +720.9% | 0.42% | +926.8% |
| Q4 2018 | $384,000 | -88.3% | 8,353 | -88.7% | 0.04% | -84.5% |
| Q3 2018 | $3,287,000 | +11.8% | 74,071 | -1.3% | 0.26% | +27.5% |
| Q2 2018 | $2,940,000 | -40.9% | 75,020 | +9.1% | 0.21% | -41.9% |
| Q1 2018 | $4,973,000 | +0.3% | 68,748 | +13.4% | 0.36% | +12.3% |
| Q2 2015 | $4,957,000 | -26.6% | 60,630 | -16.8% | 0.32% | -24.9% |
| Q1 2015 | $6,751,000 | +316.2% | 72,909 | +81.8% | 0.42% | +317.8% |
| Q4 2014 | $1,622,000 | +175.4% | 40,104 | +66.6% | 0.10% | +173.0% |
| Q3 2014 | $589,000 | – | 24,070 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |